Price comparison of Selinexor tablets and market differences of different specifications

Selinexor (Selinexor), as a first-in-class selective nuclear export inhibitor (SINE), has played an important role in the treatment of malignant hematological diseases such as multiple myeloma and some lymphomas. The drug is currently on the market in China and has been included in the scope of medical insurance reimbursement, allowing more patients to obtain standardized treatment at a relatively affordable price. In the domestic market, the selling price of Seleniso ranges from approximately RMB 5,000 to more than RMB 10,000. The purchasing channels and packaging specifications of different hospitals and pharmacies may lead to certain differences in the actual selling price. After medical insurance reimbursement, the patient's out-of-pocket payment ratio has been significantly reduced, and the overall financial burden has been alleviated.

In terms of specifications, the main form of Seleniso sold domestically is tablet packaging, and different dosages and number of tablets will directly affect the total price. Generally speaking, the price of a single tablet in large packaging is lower and is suitable for patients with long-term regular treatment; while the small packaging is convenient for short-term treatment or dosage adjustment when patients first start treatment. Since selinesol is an oral preparation, patients need to adhere to it for a long time during the medication. Therefore, choosing the appropriate specifications can not only meet the efficacy needs, but also reduce the economic burden to a certain extent.

In addition to domestic original drugs, there are also foreign generic versions on the market. In particular, the price of the Lao version of the generic Seleniso is relatively more affordable. Each box costs about more than 2,000 yuan, and the cost is much lower than that of the domestic original drug. This version is consistent with the original drug in terms of active ingredients and main efficacy, making it an important choice for some patients with limited economic conditions. However, when choosing generic drugs, patients should ensure that they purchase them through formal channels to avoid purchasing products of substandard quality or from unknown sources.

Overall, the domestic launch and medical insurance coverage of Seleniso have significantly improved its accessibility, but the price still poses a certain pressure on some patients. For patients with better economic conditions, they can directly purchase original drugs after reimbursement by medical insurance through regular hospital pharmacies; while for patients with heavier burdens, overseas generic drugs such as the Lao version provide certain alternatives. In the future, as more generic drugs enter the market and medical insurance policies are further optimized, the price of seliniso is expected to gradually decrease, thereby benefiting more patients who require long-term treatment.

Reference link:https://www.drugs.com